|1.||Mihara, Kayoko: 1 article (09/2004)|
|2.||Matsuura, Shigeru: 1 article (09/2004)|
|3.||Ishida, Junya: 1 article (09/2004)|
|4.||Mutoh, Seitaro: 1 article (09/2004)|
|5.||Matsuoka, Nobuya: 1 article (09/2004)|
|6.||Hattori, Kouji: 1 article (09/2004)|
|7.||Iwashita, Akinori: 1 article (09/2004)|
|8.||Yamazaki, Syunji: 1 article (09/2004)|
|9.||Yamamoto, Hirofumi: 1 article (09/2004)|
|1.||Parkinson Disease (Parkinson's Disease)
09/01/2004 - "In this study, we show that prevention of PARP activation by treatment with FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], the compound that was recently identified as a novel PARP inhibitor (IC50 for PARP-1 = 33 nM, IC50 for PARP-2 = 7 nM), protects against both ROS-induced cells injury in vitro and METH-induced dopaminergic neuronal damage in an in vivo Parkinson's disease (PD) model. "
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
09/01/2004 - "These findings indicate that the neuroprotective effects of a novel PARP inhibitor, FR261529, were accompanied by inhibition of METH-induced PARP activation, suggesting that METH induces nigrostriatal dopaminergic neurodegeneration involving PARP activation and also orally active and brain-penetrable PARP inhibitor FR261529 could be a novel attractive therapeutic candidate for neurodegenerative disorders such as PD."